Skip to main content
. 2007 Nov 16;104(48):19040–19045. doi: 10.1073/pnas.0702544104

Fig. 1.

Fig. 1.

Plexin-B1 expression in prostate cancer. (a) RT-PCR and BstZ171 restriction enzyme digestion of RNA from PC3 (lane 1), LNCaP (lane 2), and DU145 (lane 3). The A5359G mutation in LNCaP destroys a BstZ171 site. Band sizes in base pairs are shown. (b) PCR of genomic DNA and BstZ171 restriction enzyme digestion. Shown are undigested DNA (lane 1), PC3 DNA digested with BstZ171 (lane 2), and LNCaP DNA digested with BstZ171 (lane 3). The A5359G mutation in LNCaP destroys a BstZ171 site. (c) Quantitative RT-PCR of RNA from LNCaP, DU145, and PC3 cells. Results are the average of three independent RNA extractions normalized to PC3 expression. (d) Nonneoplastic (i and ii) and primary cancer (iii and iv) tissue stained with H&E (i and iii) or antibody to Plexin-B1 (ii and iv). (Magnification, ×400.) (e) Nonneoplastic (i) and primary cancer (ii) tissue stained with antibody to Sema4D. (Magnification, ×400.) (f) Quantitative RT-PCR of RNA from paired samples of nonneoplastic tissue and primary cancer from the same patient (patients 1–6) normalized to nonneoplastic tissue from patient 1.